Biodesix INC (NASDAQ:BDSX) Chief Development Officer Gary Anthony Pestano executed a sale of 556 common shares on February 23, 2026, generating about $7,103 in proceeds. The shares sold at a weighted average of $12.7756 apiece, with trade prices spanning from $12.58 to $13.16.
This disposition came while the stock was trading near an InvestingPro Fair Value of $13.12, and after a year-to-date rally that has delivered an 88% return for the shares. Biodesix’s market capitalization at the time of the transaction is reported at $102.87 million.
Earlier in the week, on February 20, Pestano increased his holdings by 1,528 shares through the exercise of restricted stock units. After the combination of the RSU exercise and the subsequent sale, Pestano’s direct ownership in Biodesix stands at 10,359 common shares.
InvestingPro, which is cited in relation to the company’s fair value, indicates it provides six additional exclusive tips for BDSX. The company is scheduled to report quarterly results on March 4, a date noted as eight days away from the transaction date.
Separately, Biodesix disclosed preliminary financial results for the fourth quarter and full year 2025 that exceeded both analyst expectations and the firm's own guidance. The company reported fourth-quarter revenue of $28.8 million, representing a 41% increase from the same quarter a year earlier.
For the full year, Biodesix estimated revenue of $88.5 million, a 24% year-over-year increase that also surpassed the company’s previously raised guidance range of $84 million to $86 million. Management’s preliminary figures indicate the company achieved EBITDA profitability for the period.
Analysts have taken note of the preliminary results, though the reporting does not include any specific analyst upgrades or downgrades tied to the announcement. The company’s ability to top its revenue guidance has been highlighted as evidence of robust performance in the diagnostic solutions sector.
All figures and ownership data reported above reflect the disclosures and estimates cited in company-related materials and InvestingPro notes.